Skip to main content

AbbVie on track for biggest decline in about three years as newer drug sales lag estimates

Investors were expecting the 25% decline in sales of blockbuster Humira which has lost its patent exclusivity, but newer drugs fell short of estimates.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.